Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 2, 2007, Pages 116-123

  Kador, Peter F ^a,b,c   Randazzo, James ^a   Babb, Thomas ^a   Koushik, Kavitha ^a   Takamura, Yoshihiro ^b   Zhu, Wenjun ^a   Blessing, Karen ^a   Kompella, Uday B ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLSORBINIL; ALDOSE REDUCTASE INHIBITOR; CARBOMER; GALACTOSE; GELLAN; HYDROXYPROPYLMETHYLCELLULOSE; XANTHAN;

ALKALINITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CARBOHYDRATE INTAKE; CATARACT; CONTROLLED STUDY; DISEASE MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; EVALUATION; LENS; MALE; NONHUMAN; RAT; SLIT LAMP; SPRAGUE DAWLEY RAT; VISCOSITY;

ADMINISTRATION, TOPICAL; ALDEHYDE REDUCTASE; ANIMALS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CATARACT; CORNEA; DRUG CARRIERS; ENZYME INHIBITORS; GALACTOSE; HYDROGEN-ION CONCENTRATION; IMIDAZOLIDINES; LENS, CRYSTALLINE; MALE; MYDRIASIS; OPHTHALMIC SOLUTIONS; RATS; RATS, SPRAGUE-DAWLEY; VACUOLES; VEHICLES; VISCOSITY;

EID: 34247383873     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.0112     Document Type: Article

References (27)

1. Bourlais, C.L., Acar, L., Zia, H., et al. Ophthalmic drug delivery systems - recent advances. Prog. Retin. Eye Res. 17:33-58, 1998.
2. Davies, N.M. Biopharmaceutical considerations in topical ocular drug delivery. Clin. Exp. Pharmacol. Physiol. 27:558-562, 2000.
3. van Ooteghem, M. Formulation of Ophthalmic Solutions and Suspensions: Problems and Advantages. Boca Raton, FL: CRC Press, 1993:202.
4. Head, K.A. Natural therapies for ocular disorders, part two: Cataracts and glaucoma. Altern. Med. Rev. 6:141-166, 2001.
5. Kador, P.F., and Kinoshita, J.H. Diabetic and galactosaemic cataracts. Ciba. Found. Symp. 106:110-131, 1984.
6. Chanalet, L., and Lapalus, P. Drugs designed to maintain the transparence of the ocular lens. Fund. Clin. Pharmacol. 8:322-341, 1994.
7. Kador, P.F. Ocular pathology of diabetes mellitus. In Tasman, W. and Jaeger, E.A., eds. Duane's Ophthalmology, Lippincott Williams & Wilkins, Philadelphia, PA. 2007 edition.
8. Peterson, M.J., Sarges, R., Aldinger, C.E., et al. CP-45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Metabolism 28:456-461, 1979.
9. Datiles, M., Fukui, H., Kuwabara, T., et al. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: A light microscopic study. Invest. Ophthalmol. Vis. Sci. 22:174-179, 1982.
10. Unakar, N.J., and Tsui, J.Y. Inhibition of galactose-induced alterations in ocular lens with sorbinil. Exp. Eye Res. 36:685-694, 1983.
11. Akagi, Y., Kador, P.F., Kinoshita, J.H., et al. [Prevention and reversal of rat galactosemic cataract with aldose reductase inhibitor - immunohistochemical study]. Nippon Ganka Gakkai Zasshi 89:1276-1281, 1985.
12. Tasaka, H., Akagi, Y., Yoshikawa, T., et al. [Prevention of rat galactose cataract with topical aldose reductase inhibitor, E-1008]. Nippon Ganka Gakkai Zasshi 91:246-253, 1987.
13. Unakar, N., Tsui, J., and Johnson, M. Aldose reductase inhibitors and prevention of galactose cataracts in rats. Invest. Ophthalmol. Vis. Sci. 30:1623-1632, 1989.
14. Unakar, N.J., Tsui, J.Y., and Johnson, M.J. Prefeeding of aldose reductase inhibitor and galactose cataractogenesis. Curr. Eye Res. 8:997-1010, 1989.
15. Sato, S., Mori, K., Wyman, M., et al. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175. Exp. Eye Res. 66:217-222, 1998.
16. Kador, P.F. Biochemistry of the Lens: Intermediary Metabolism and Sugar Cataract Formation. Philadelphia: W.B. Saunders Co. 1994:146-167.
17. Crabbe, M.J., Petchey, M., Burgess, S.E., et al. The penetration of Sorbinil, an aldose reductase inhibitor, into lens, aqueous humour, and erythrocytes of patients undergoing cataract extraction. Exp. Eye Res. 40:95-99, 1985.
18. Hockwin, O., Muller, P., Krolczyk, J., et al. Determination of AL01576 concentration in rat lenses and plasma by bioassay for aldose reductase activity measurements. Ophthalmic Res. 21:285-291, 1989.
19. Ao, S., Kikuchi, C., Ono, T., et al. Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract. Invest. Ophthalmol. Vis. Sci. 32:3078-3083, 1991.
20. Banditelli, S., Boldrini, E., Vilardo, P.G., et al. A new approach against sugar cataract through aldose reductase inhibitors. Exp. Eye Res. 69:533-538, 1999.
21. Dirlam, N.L., Moore, B.S., and Urban, F.J. Novel synthesis of the aldose reductase inhibitor sorbinil via amidoalkylation, intramolecular oxazolidin-5-one alkylation and chymotrypsin resolution. J. Org. Chem. 52:3587-3591, 1987.
22. Wang, M., Mishra, M.K., Zhu, W., et al. Spectral assignments for the aldose reductase inhibitor 4(S)-2,3-dihydro-6-fluoro-2(R)-methylspiro[chroman-4, 4′-imidazoline]-2′,5′-dione and its synthetic intermediates. Magn. Reson. Chem. 43:1008-1011, 2005.
23. Williams, D.L. Analysis of tear uptake by the Schirmer tear test strip in the canine eye. Vet. Ophthalmol. 8:325-330, 2005.
24. Yagi, N. Comparison of thread test of lacrimation to Schirmer test. Ann. Otol. Rhinol. Laryngol. Suppl. 122: 3-6, 1986.
25. Gelatt, K.N., Peiffer, R.L., Jr., Erickson, J.L., et al. Evaluation of tear formation in the dog, using a modification of the Schirmer tear test. J. Am. Vet. Med. Assoc. 166:368-370, 1975.
26. Kato, A., Horie, T., Ishibashi, Y., et al. Corneal permeability of aldose reductase inhibitor, M79175. II. In vivo study on pharmacokinetic aspect. J. Ocul. Pharmacol. Ther. 2:287-294, 1986.
27. Brazzell, R.K., Wooldridge, C.B., Hackett, R.B., et al. Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration. Pharm. Res. 7:192-198, 1990.